Payment overview · 2025
General Payments
$1,389.70
47 reported records · 9 companies
Healthcare provider profile · identity verified
Darrell Scott Parsons, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ODESSA, TX · NPI 1144212440
Verified facts
What the public records show
CMS Open Payments records show Darrell Scott Parsons, M.D. received $1,389.70 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $274.05 | 19.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $256.05 | 18.4% | 15 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $199.17 | 14.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $182.37 | 13.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $180.74 | 13.0% | 9 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $125.00 | 9.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.83 | 6.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.18 | 3.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.31 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,389.70 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $258.61 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $230.95 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $210.02 | 12 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $199.17 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $182.37 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $134.29 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $96.38 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.07 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.22 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.18 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.45 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.45 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.93 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.10 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $8.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 35 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 301 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 299 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 354 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
301 | 76 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
299 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
145 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
354 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
301 | 76 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1149 | 349 |
| Levothyroxine Sodium | Levothyroxine Sodium | 793 | 219 |
| Pantoprazole Sodium | Pantoprazole Sodium | 741 | 244 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 737 | 219 |
| Losartan Potassium | Losartan Potassium | 675 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 165 |
| Carvedilol | Carvedilol | 460 | 135 |
| Metformin Hcl | Metformin Hcl | 459 | 157 |
| Lisinopril | Lisinopril | 402 | 118 |
| Ozempic | Semaglutide | 354 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 111 |
| Furosemide | Furosemide | 329 | 131 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 310 | 97 |
| Eliquis | Apixaban | 301 | 76 |
| Mounjaro | Tirzepatide | 299 | 61 |
| Allopurinol | Allopurinol | 298 | 92 |
| Felodipine Er | Felodipine | 294 | 103 |
| Methylprednisolone | Methylprednisolone | 287 | 200 |
| Tresiba Flextouch U-200 | Insulin Degludec | 279 | 76 |
| Gabapentin | Gabapentin | 253 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 248 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 95 |
| Potassium Chloride | Potassium Chloride | 239 | 85 |
| Irbesartan | Irbesartan | 233 | 64 |
| Azithromycin | Azithromycin | 231 | 190 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 69 |
| Telmisartan | Telmisartan | 211 | 62 |
| Spironolactone | Spironolactone | 210 | 77 |
| Nifedipine Er | Nifedipine | 191 | 61 |
| Omeprazole | Omeprazole | 185 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 48 |
| Trulicity | Dulaglutide | 145 | 45 |
| Finasteride | Finasteride | 139 | 41 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 139 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 42 |
| Donepezil Hcl | Donepezil Hcl | 127 | 38 |
| Cefdinir | Cefdinir | 121 | 101 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 120 | 35 |
| Alprazolam | Alprazolam | 115 | 26 |
| Tramadol Hcl | Tramadol Hcl | 107 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 23 |
| Metformin Hcl Er | Metformin Hcl | 86 | 28 |
| Ezetimibe | Ezetimibe | 85 | 29 |
| Montelukast Sodium | Montelukast Sodium | 82 | 28 |
| Bumetanide | Bumetanide | 80 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 24 |
| Estradiol | Estradiol | 71 | 19 |
| Simvastatin | Simvastatin | 70 | 24 |
| Trazodone Hcl | Trazodone Hcl | 70 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 42 |
| Synthroid | Levothyroxine Sodium | 63 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 17 |
| Pregabalin | Pregabalin | 60 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 19 |
| Levofloxacin | Levofloxacin | 56 | 50 |
| Prednisone | Prednisone | 54 | 35 |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 42 |
| Xarelto | Rivaroxaban | 49 | 12 |
| Atenolol | Atenolol | 48 | 12 |
| Ramipril | Ramipril | 47 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 38 |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 15 |
| Sertraline Hcl | Sertraline Hcl | 43 | 16 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 18 |
| Mupirocin | Mupirocin | 40 | 29 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 38 | 12 |
| Fluconazole | Fluconazole | 37 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 35 | 35 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 17 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Lyumjev Kwikpen U-200 | Insulin Lispro-Aabc | 30 | 12 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Valacyclovir | Valacyclovir Hcl | 28 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Famotidine | Famotidine | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 14 |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 17 |
| Metolazone | Metolazone | 21 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,389.70 · 47 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, Saxenda, TARPEYO, UBRELVY, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error